 Jason Kolfenbach
Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rheumatology | 7 | 2023 | 107 | 1.720 |
Why?
| | Rheumatic Diseases | 3 | 2023 | 69 | 0.970 |
Why?
| | Takayasu Arteritis | 1 | 2025 | 15 | 0.960 |
Why?
| | Non-ST Elevated Myocardial Infarction | 1 | 2025 | 19 | 0.950 |
Why?
| | Arthritis, Rheumatoid | 9 | 2023 | 1098 | 0.900 |
Why?
| | Autoimmune Diseases | 2 | 2019 | 428 | 0.760 |
Why?
| | Triage | 1 | 2019 | 207 | 0.530 |
Why?
| | Autoantibodies | 6 | 2015 | 1468 | 0.440 |
Why?
| | Connective Tissue Diseases | 1 | 2011 | 82 | 0.340 |
Why?
| | Hydrolases | 1 | 2010 | 56 | 0.330 |
Why?
| | Myelitis | 1 | 2011 | 98 | 0.330 |
Why?
| | Antirheumatic Agents | 2 | 2023 | 280 | 0.330 |
Why?
| | Granulomatosis with Polyangiitis | 2 | 2020 | 43 | 0.330 |
Why?
| | Neuromyelitis Optica | 1 | 2011 | 129 | 0.320 |
Why?
| | Family Health | 1 | 2009 | 198 | 0.300 |
Why?
| | Peptides, Cyclic | 5 | 2015 | 256 | 0.290 |
Why?
| | Rheumatoid Factor | 4 | 2015 | 167 | 0.270 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2025 | 577 | 0.270 |
Why?
| | Scleroderma, Diffuse | 1 | 2025 | 4 | 0.240 |
Why?
| | Education, Medical, Graduate | 3 | 2023 | 443 | 0.230 |
Why?
| | Curriculum | 4 | 2023 | 928 | 0.230 |
Why?
| | Drug-Eluting Stents | 1 | 2025 | 74 | 0.230 |
Why?
| | Echocardiography, Transesophageal | 1 | 2025 | 93 | 0.230 |
Why?
| | Telemedicine | 2 | 2023 | 792 | 0.220 |
Why?
| | Coronary Artery Bypass | 1 | 2025 | 224 | 0.210 |
Why?
| | Immunosuppressive Agents | 3 | 2025 | 858 | 0.210 |
Why?
| | Coronary Angiography | 1 | 2025 | 306 | 0.200 |
Why?
| | Keratoconjunctivitis Sicca | 1 | 2022 | 5 | 0.200 |
Why?
| | Scleritis | 1 | 2022 | 19 | 0.200 |
Why?
| | Corneal Ulcer | 1 | 2022 | 16 | 0.200 |
Why?
| | Genetic Predisposition to Disease | 2 | 2012 | 2271 | 0.190 |
Why?
| | Electrocardiography | 1 | 2025 | 613 | 0.190 |
Why?
| | Methotrexate | 3 | 2021 | 249 | 0.190 |
Why?
| | Rheumatologists | 2 | 2023 | 15 | 0.190 |
Why?
| | Autoimmunity | 3 | 2012 | 863 | 0.180 |
Why?
| | Educational Status | 1 | 2023 | 474 | 0.180 |
Why?
| | Humans | 23 | 2025 | 129847 | 0.160 |
Why?
| | Aftercare | 1 | 2021 | 206 | 0.160 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2025 | 467 | 0.160 |
Why?
| | Retinal Diseases | 1 | 2020 | 87 | 0.160 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2021 | 247 | 0.150 |
Why?
| | Adult | 11 | 2025 | 35634 | 0.150 |
Why?
| | Patient Selection | 2 | 2019 | 660 | 0.140 |
Why?
| | Behcet Syndrome | 1 | 2016 | 18 | 0.130 |
Why?
| | Ophthalmologists | 1 | 2016 | 12 | 0.130 |
Why?
| | Azathioprine | 1 | 2016 | 50 | 0.130 |
Why?
| | Patient Readmission | 1 | 2021 | 668 | 0.130 |
Why?
| | Arthritis, Juvenile | 1 | 2016 | 53 | 0.120 |
Why?
| | Female | 13 | 2025 | 68829 | 0.120 |
Why?
| | Eye Diseases | 1 | 2016 | 82 | 0.120 |
Why?
| | Drug Costs | 1 | 2016 | 100 | 0.120 |
Why?
| | Vision Disorders | 1 | 2016 | 135 | 0.120 |
Why?
| | Glucocorticoids | 2 | 2016 | 582 | 0.120 |
Why?
| | Uveitis | 1 | 2016 | 127 | 0.120 |
Why?
| | Quality Improvement | 1 | 2021 | 1112 | 0.100 |
Why?
| | Disease Progression | 2 | 2011 | 2628 | 0.100 |
Why?
| | Health Care Costs | 1 | 2016 | 367 | 0.100 |
Why?
| | Middle Aged | 9 | 2025 | 31177 | 0.100 |
Why?
| | Internship and Residency | 1 | 2022 | 1058 | 0.100 |
Why?
| | Transplantation, Autologous | 2 | 2025 | 213 | 0.090 |
Why?
| | Bronchial Diseases | 1 | 2011 | 37 | 0.090 |
Why?
| | Chemokines | 1 | 2012 | 227 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1560 | 0.090 |
Why?
| | C-Reactive Protein | 2 | 2012 | 401 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 836 | 0.090 |
Why?
| | Protein-Arginine Deiminases | 1 | 2010 | 16 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 2 | 2016 | 1274 | 0.090 |
Why?
| | Risk Factors | 4 | 2025 | 9801 | 0.090 |
Why?
| | Patient Care Planning | 1 | 2011 | 146 | 0.090 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2009 | 46 | 0.080 |
Why?
| | Fellowships and Scholarships | 2 | 2023 | 279 | 0.080 |
Why?
| | Male | 10 | 2025 | 63759 | 0.080 |
Why?
| | Aged | 6 | 2025 | 22107 | 0.070 |
Why?
| | Prospective Studies | 3 | 2025 | 7158 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2020 | 2344 | 0.070 |
Why?
| | Lung Diseases | 1 | 2011 | 743 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 1951 | 0.060 |
Why?
| | Antilymphocyte Serum | 1 | 2025 | 63 | 0.060 |
Why?
| | Inflammation | 2 | 2012 | 2748 | 0.060 |
Why?
| | Cohort Studies | 2 | 2012 | 5444 | 0.060 |
Why?
| | Cyclophosphamide | 1 | 2025 | 234 | 0.060 |
Why?
| | Mycophenolic Acid | 1 | 2025 | 110 | 0.060 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2724 | 0.050 |
Why?
| | Biological Factors | 1 | 2022 | 36 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 2062 | 0.050 |
Why?
| | Accreditation | 1 | 2022 | 80 | 0.050 |
Why?
| | Needs Assessment | 1 | 2023 | 357 | 0.040 |
Why?
| | Young Adult | 2 | 2021 | 12467 | 0.040 |
Why?
| | Contraceptive Agents | 1 | 2021 | 65 | 0.040 |
Why?
| | Oximes | 1 | 2020 | 22 | 0.040 |
Why?
| | Time Factors | 1 | 2010 | 6550 | 0.040 |
Why?
| | Internal Medicine | 1 | 2022 | 247 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 1847 | 0.040 |
Why?
| | Fluorescein Angiography | 1 | 2020 | 143 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2020 | 102 | 0.040 |
Why?
| | Contraception | 1 | 2021 | 153 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 164 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2020 | 284 | 0.040 |
Why?
| | Imidazoles | 1 | 2020 | 235 | 0.040 |
Why?
| | Pyridones | 1 | 2020 | 158 | 0.040 |
Why?
| | Biomarkers | 1 | 2009 | 3971 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2025 | 10241 | 0.040 |
Why?
| | Adolescent | 2 | 2021 | 20451 | 0.040 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 210 | 0.040 |
Why?
| | United States | 2 | 2016 | 13913 | 0.030 |
Why?
| | Administration, Topical | 1 | 2016 | 147 | 0.030 |
Why?
| | Specialization | 1 | 2016 | 145 | 0.030 |
Why?
| | Ophthalmology | 1 | 2016 | 82 | 0.030 |
Why?
| | Clinical Competence | 1 | 2022 | 1020 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1500 | 0.030 |
Why?
| | Immunoglobulins | 1 | 2015 | 162 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2016 | 558 | 0.030 |
Why?
| | Insurance, Health | 1 | 2016 | 269 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2016 | 5437 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 304 | 0.030 |
Why?
| | Interleukin-9 | 1 | 2012 | 9 | 0.020 |
Why?
| | Arthrography | 1 | 2011 | 17 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 147 | 0.020 |
Why?
| | Patient Care Team | 1 | 2016 | 603 | 0.020 |
Why?
| | Interleukin-2 | 1 | 2012 | 437 | 0.020 |
Why?
| | Joints | 1 | 2011 | 101 | 0.020 |
Why?
| | Decision Making | 1 | 2016 | 864 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2012 | 773 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 6423 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2012 | 724 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 1989 | 0.020 |
Why?
| | Cytokines | 1 | 2012 | 2022 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2021 | 14553 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3062 | 0.010 |
Why?
| | Child | 1 | 2016 | 20962 | 0.010 |
Why?
|
|
Kolfenbach's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|